Metrics as of 10/17/2026, 05:16 AM (Berlin time), refresh in progress.
Hoth Therapeutics Stock
Hoth Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Robb Knie
- Employees
- 6
- Market cap
- $11 M
- IPO
- 15/02/2019
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug…
Hoth Therapeutics stock: price history
1D
+25.0%
1W
+165.6%
1M
+131.5%
6M
+41.7%
YTD
+71.7%
1Y
+100.6%
2Y
+46.6%
5Y
-95.3%
10Y
–
Next earnings date
Next earnings date
No date known
Volatility around earnings
~33% weaker price swings than usual
Ask the agents about Hoth Therapeutics
Analyst assessment of Hoth Therapeutics
0
STRONG BUY
4
BUY
0
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 25/03/2026
Hoth Therapeutics stock metrics
P/E
-0.97
P/B
2.01
EV/EBITDA
-0.21
RETURN ON EQUITY
-46.8%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
95.8%
FLOAT SHARES
12,705,463
AVG. DAILY VOLUME (30D)
9,437,392
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Hoth Therapeutics stock
What does Hoth Therapeutics do?
Hoth Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Robb Knie, the company employs around 6 people.
The IPO was on 15/02/2019; the stock trades on NASDAQ under the ticker HOTH.
What do analysts say about Hoth Therapeutics stock?
4 analysts rate the stock, the consensus is Buy (as of 25/03/2026).
This is an external assessment, not a statement by Market Jury.
When does Hoth Therapeutics report next?
Around past earnings, price swings were roughly -33% stronger than usual.
Does Hoth Therapeutics pay a dividend?
No, Hoth Therapeutics currently does not pay a dividend.
Which stocks are comparable to Hoth Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Hoth Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Hoth Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.